Predicting response to EGFR inhibitors in metastatic colorectal cancer: Current practice and future directions

Veena Shankaran, Jennifer Obel, Al B. Benson

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

The identification of KRAS mutational status as a predictive marker of response to antibodies against the epidermal growth factor receptor (EGFR) has been one of the most significant and practice-changing recent advances in colorectal cancer research. Recently, data suggesting a potential role for other markers (including BRAF mutations, loss of phosphatase and tensin homologue deleted on chromosome ten expression, and phosphatidylinositol-3-kinase-AKT pathway mutations) in predicting response to anti-EGFR therapy have emerged. Ongoing clinical trials and correlative analyses are essential to definitively identify predictive markers and develop therapeutic strategies for patients who may not derive benefit from anti-EGFR therapy. This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.

Original languageEnglish (US)
Pages (from-to)157-167
Number of pages11
JournalOncologist
Volume15
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Epidermal Growth Factor Receptor
Colorectal Neoplasms
Clinical Trials
Phosphatidylinositol 3-Kinase
Mutation
Phosphoric Monoester Hydrolases
Antibody Formation
Therapeutics
Chromosomes
Guidelines
Research
Pharmaceutical Preparations
Direction compound

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{186467cf5a6c4a28b33a251853b4c670,
title = "Predicting response to EGFR inhibitors in metastatic colorectal cancer: Current practice and future directions",
abstract = "The identification of KRAS mutational status as a predictive marker of response to antibodies against the epidermal growth factor receptor (EGFR) has been one of the most significant and practice-changing recent advances in colorectal cancer research. Recently, data suggesting a potential role for other markers (including BRAF mutations, loss of phosphatase and tensin homologue deleted on chromosome ten expression, and phosphatidylinositol-3-kinase-AKT pathway mutations) in predicting response to anti-EGFR therapy have emerged. Ongoing clinical trials and correlative analyses are essential to definitively identify predictive markers and develop therapeutic strategies for patients who may not derive benefit from anti-EGFR therapy. This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.",
author = "Veena Shankaran and Jennifer Obel and Benson, {Al B.}",
year = "2010",
month = "2",
day = "1",
doi = "10.1634/theoncologist.2009-0221",
language = "English (US)",
volume = "15",
pages = "157--167",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "2",

}

Predicting response to EGFR inhibitors in metastatic colorectal cancer : Current practice and future directions. / Shankaran, Veena; Obel, Jennifer; Benson, Al B.

In: Oncologist, Vol. 15, No. 2, 01.02.2010, p. 157-167.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Predicting response to EGFR inhibitors in metastatic colorectal cancer

T2 - Current practice and future directions

AU - Shankaran, Veena

AU - Obel, Jennifer

AU - Benson, Al B.

PY - 2010/2/1

Y1 - 2010/2/1

N2 - The identification of KRAS mutational status as a predictive marker of response to antibodies against the epidermal growth factor receptor (EGFR) has been one of the most significant and practice-changing recent advances in colorectal cancer research. Recently, data suggesting a potential role for other markers (including BRAF mutations, loss of phosphatase and tensin homologue deleted on chromosome ten expression, and phosphatidylinositol-3-kinase-AKT pathway mutations) in predicting response to anti-EGFR therapy have emerged. Ongoing clinical trials and correlative analyses are essential to definitively identify predictive markers and develop therapeutic strategies for patients who may not derive benefit from anti-EGFR therapy. This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.

AB - The identification of KRAS mutational status as a predictive marker of response to antibodies against the epidermal growth factor receptor (EGFR) has been one of the most significant and practice-changing recent advances in colorectal cancer research. Recently, data suggesting a potential role for other markers (including BRAF mutations, loss of phosphatase and tensin homologue deleted on chromosome ten expression, and phosphatidylinositol-3-kinase-AKT pathway mutations) in predicting response to anti-EGFR therapy have emerged. Ongoing clinical trials and correlative analyses are essential to definitively identify predictive markers and develop therapeutic strategies for patients who may not derive benefit from anti-EGFR therapy. This article reviews recent clinical trials supporting the predictive role of KRAS, recent changes to clinical guidelines and pharmaceutical labeling, investigational predictive molecular markers, and newer clinical trials targeting patients with mutated KRAS.

UR - http://www.scopus.com/inward/record.url?scp=77649156753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649156753&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2009-0221

DO - 10.1634/theoncologist.2009-0221

M3 - Review article

C2 - 20133499

AN - SCOPUS:77649156753

VL - 15

SP - 157

EP - 167

JO - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 2

ER -